Sue Hughes

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction and obesity.

With growing evidence that loneliness increases the risk for multiple diseases, there are questions about the mechanisms at play and what clinicians can do to help patients.

Extending the simple CT scan administered to all acute stroke patients to include the upper part of the heart increased cardioaortic thrombus detection by almost sixfold.

The long-standing debate as to when to start anticoagulation in patients with an acute ischemic stroke and atrial fibrillation looks as though it is settled.

Evidence is rising in favor of using highly effective DMTs to treat pediatric MS, but with few licensed for pediatric use, it may be time to rethink the standard treatment approach.

Single-pill combinations of three or more antihypertensive drugs are the way forward to help patients reach lower blood pressure targets, according to experts evaluating the approach.

Results of the HELIOS-B trial indicate patients may soon have a second drug class available to slow the progression of transthyretin-mediated amyloidosis with cardiomyopathy, a fatal disease.

It does not matter whether antihypertensive medication is taken in the morning or at bedtime, two new trials confirm.

The long-debated question of whether mineralocorticoid receptor antagonists are effective for heart failure with mildly reduced or preserved ejection fraction has been answered in a new trial.

Simplified and more aggressive targets are among the significant changes to the updated hypertension guidelines by the European Society of Cardiology.